Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.1
Journals
JPM
Special Issues
Recent Advances in Precision Medicine: Personalized Therapy, Drug Delivery and...
share announcement

Recent Advances in Precision Medicine: Personalized Therapy, Drug Delivery and Nanomedicine

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Personalized Therapy and Drug Delivery".

Deadline for manuscript submissions: closed (15 November 2024) | Viewed by 10290

Special Issue Editors

Prof. Dr. Liang Cheng

grade E-Mail Website
Guest Editor
Legorreta Cancer Center at Brown University, Departments of Pathology and Surgery/Urology, Brown University Warren Alpert Medical School, Providence, RI, USA
Interests: urologic pathology (bladder cancer, prostate cancer, kidney cancer, testicular cancer); molecular diagnostics; molecular pathology of solid tumors
Special Issues, Collections and Topics in MDPI journals
Dr. Benedito A. Carneiro

E-Mail Website
Guest Editor
Legorreta Cancer Center at Brown University, Division of Hematology/Oncology, The Warren Alpert Medical School, Providence, RI, USA
Interests: oncology; hematology
Dr. Chong-Xian Pan

E-Mail Website
Guest Editor
Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
Interests: oncology; hematology

Special Issue Information

Dear Colleagues,

Personalized therapy is an emerging research area for disease treatment taking into account individual difference in genes, environment and lifestyles. Nanomedicine and targeted drug delivery allow us to rapidly and accurately detect disease and develop highly effective treatments.

We hope to review the recent advances and upcoming technologies that will define how we can provide personalized treatment supported by individual patient or tumor molecular features or tailored to specific patient populations through targeted drug delivery. This Special Issue will cover established, new, and upcoming potential drugs, novel diagnostic modalities and therapeutic strategies, genomic discovery, nanomedicine, and cutting-edge technologies employed at all stages of target and drug discovery, validation, and delivery. It will also explore the role of machine learning in refining the understanding of mechanisms of resistance and signaling within complex pathophysiological systems.

We invite established investigators to contribute with original research and review articles. The submission deadline is May 1, 2023.

Sincerely,

Prof. Dr. Liang Cheng
Dr. Benedito A. Carneiro
Dr. Chong-Xian Pan
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • personalized therapy
  • drug delivery
  • precision genomics
  • nanomedicine
  • therapeutic strategies
  • machine learning
  • cancers
  • precision oncology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

14 pages, 2053 KiB  
Article
Analysis of Clinical Trials and Review of Recent Advances in Therapy Decisions for Locally Advanced Prostate Cancer
by Norman R. Williams
J. Pers. Med. 2023, 13(6), 938; https://doi.org/10.3390/jpm13060938 - 1 Jun 2023
Cited by 1 | Viewed by 2408
Abstract
Despite the implementation of screening and early detection in many countries, the prostate cancer mortality rate remains high, particularly when the cancer is locally advanced. Targeted therapies with high efficacy and minimal harms should be particularly beneficial in this group, and several new [...] Read more.
Despite the implementation of screening and early detection in many countries, the prostate cancer mortality rate remains high, particularly when the cancer is locally advanced. Targeted therapies with high efficacy and minimal harms should be particularly beneficial in this group, and several new approaches show promise. This article briefly analyses relevant clinical studies listed on ClinicalTrials.gov, combined with a short literature review that considers new therapeutic approaches that can be investigated in future clinical trials. Therapies using gold nanoparticles are of special interest in low-resource settings as they can localize and enhance the cancer-cell killing potential of X-rays using equipment that is already widely available. Full article
(This article belongs to the Special Issue Recent Advances in Precision Medicine: Personalized Therapy, Drug Delivery and Nanomedicine)
►▼ Show Figures

Figure 1

Other

Jump to: Research

22 pages, 1537 KiB  
Systematic Review
Precision Medicine on the Effects of Microbiota on Head–Neck Diseases and Biomarkers Diagnosis
by Angelo Michele Inchingolo, Giuseppina Malcangi, Fabio Piras, Giulia Palmieri, Vito Settanni, Lilla Riccaldo, Roberta Morolla, Silvio Buongiorno, Elisabetta de Ruvo, Alessio Danilo Inchingolo, Antonio Mancini, Francesco Inchingolo, Gianna Dipalma, Stefania Benagiano, Gianluca Martino Tartaglia and Assunta Patano
J. Pers. Med. 2023, 13(6), 933; https://doi.org/10.3390/jpm13060933 - 31 May 2023
Cited by 11 | Viewed by 1774
Abstract
Precision medicine using highly precise technologies and big data has produced personalised medicine with rapid and reliable diagnoses and targeted therapies. The most recent studies have directed precision medicine into the study of tumours. The application of precision medicine in the oral microbiota [...] Read more.
Precision medicine using highly precise technologies and big data has produced personalised medicine with rapid and reliable diagnoses and targeted therapies. The most recent studies have directed precision medicine into the study of tumours. The application of precision medicine in the oral microbiota can be used both in the field of prevention and treatment in the strictly dental field. This article aims to evaluate the interaction between microbiota and oral cancer and the presence of biomarkers as risk predictors. Materials and Methods: A literature search of PubMed, Scopus, and Web of Science was performed analysing the various interactions between microorganisms, biomarkers, and oral cancer. Results: After screening processes, 21 articles were selected for qualitative analysis. Conclusion: The correlation between oral diseases/cancers and changes in the microbiota explains the increasing utility of precision medicine in enhancing diagnosis and adapting treatment on the individual components of the microbiota. Diagnosing and treating oral diseases and cancers through precision medicine gives, as well as economic advantages to the health care system, predictable and rapid management of the patient. Full article
(This article belongs to the Special Issue Recent Advances in Precision Medicine: Personalized Therapy, Drug Delivery and Nanomedicine)
►▼ Show Figures

Graphical abstract

21 pages, 1633 KiB  
Systematic Review
Precision Medicine in Oral Health and Diseases: A Systematic Review
by Giuseppina Malcangi, Assunta Patano, Mariafrancesca Guglielmo, Roberta Sardano, Giulia Palmieri, Chiara Di Pede, Elisabetta de Ruvo, Alessio Danilo Inchingolo, Antonio Mancini, Francesco Inchingolo, Ioana Roxana Bordea, Gianna Dipalma and Angelo Michele Inchingolo
J. Pers. Med. 2023, 13(5), 725; https://doi.org/10.3390/jpm13050725 - 25 Apr 2023
Cited by 15 | Viewed by 3422
Abstract
Precision medicine (PM) is personalized medicine that can develop targeted medical therapies for the individual patient, in which “omics” sciences lead to an integration of data that leads to highly predictive models of the functioning of the individual biological system. They enable rapid [...] Read more.
Precision medicine (PM) is personalized medicine that can develop targeted medical therapies for the individual patient, in which “omics” sciences lead to an integration of data that leads to highly predictive models of the functioning of the individual biological system. They enable rapid diagnosis, assessment of disease dynamics, identification of targeted treatment protocols, and reduction of costs and psychological stress. “Precision dentistry” (DP) is one promising application that need further investigation; the purpose of this paper is therefore to give physicians an overview of the knowledge they need to enhance treatment planning and patient response to therapy. A systematic literature review was conducted on the PubMed, Scopus, and Web of Science databases by analyzing the articles examining the role of precision medicine in dentistry. PM aims to shed light on cancer prevention strategies, by identifying risk factors, and on malformations such as orofacial cleft. Another application is pain management by repurposing drugs created for other diseases to target biochemical mechanisms. The significant heritability of traits regulating bacterial colonization and local inflammatory responses is another result of genomic research, and is useful for DP in the field of caries and periodontitis. This approach may also be useful in the field of orthodontics and regenerative dentistry. The possibility of creating an international network of databases will lead to the diagnosis, prediction, and prevention of disease outbreaks, providing significant economic savings for the world’s health care systems. Full article
(This article belongs to the Special Issue Recent Advances in Precision Medicine: Personalized Therapy, Drug Delivery and Nanomedicine)
►▼ Show Figures

Figure 1

13 pages, 912 KiB  
Perspective
A Historical Misconception in Clinical Trials of Drugs for Cancer—Age Grouping
by Jingyu Chen, Lan Yao, Abdulmohsin J. Alamoudi, Lotfi Aleya and Weikuan Gu
J. Pers. Med. 2022, 12(12), 1998; https://doi.org/10.3390/jpm12121998 - 2 Dec 2022
Cited by 3 | Viewed by 1539
Abstract
In clinical trials of cancer drugs, grouping by age is a very common grouping method, as it can allow for a visual comparison of the different pharmaceutical responses in patients at different age stages. Under the guidance of this thinking, many researchers use [...] Read more.
In clinical trials of cancer drugs, grouping by age is a very common grouping method, as it can allow for a visual comparison of the different pharmaceutical responses in patients at different age stages. Under the guidance of this thinking, many researchers use age grouping when studying clinical cancer drugs. However, even people at the same age may be at different stages in their lives, such as individuals who are going through puberty, menopause/andropause, or intermediate transition, as well as childhood and old age, affected by factors such as hormone levels, immune responses, ethnic groups, and regions. Every individual has different cancer symptoms and responses to drugs; therefore, the experimental effect of life stage grouping will be more obvious and clearer. Not only does this conclusion apply to cancer drugs, but it also applies to clinical trials for other diseases. In addition, this does not mean that age grouping should be completely abandoned. Life stage is a more general interval that can be further divided into life stage groups according to the age of the patients. Based on the principal law of lifespan (PLOSP), age trends in life stages also need to be updated from time to time. To date, life stage grouping has not been discussed systematically and has not been used as a grouping method for cancer patients. In this paper, life stage grouping is discussed as one of the important grouping categories in cancer clinical trials. Full article
(This article belongs to the Special Issue Recent Advances in Precision Medicine: Personalized Therapy, Drug Delivery and Nanomedicine)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop